Roche RHHBY announced that the phase III CELESTIMO study, evaluating Lunsumio (mosunetuzumab) in combination with Revlimid ...

Roche (OTCQX:RHHBY) subsidiary Genentech announced on Thursday that Xofluza, an FDA-approved flu antiviral, achieved its primary goal in a global Phase 3 trial, indicating a reduction in influenza ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Roche Holdings AG (RHHBY), a pharmaceutical company, on Sunday announced promising interim results from the Phase 3 TAISHAN-302 trial conducted alongside its collaborator, MediLink Therapeutics. The ...

Roche’s ipatasertib has improved progression-free survival (PFS) in a subgroup of prostate cancer patients in a phase 3 trial. The drug failed to improve outcomes in the broader population, but, with ...

Roche Holding shares fell after the company said a late-stage study for an experimental breast-cancer treatment missed its primary objective. The results of the clinical trial mark a setback for the ...

Roche's Alzheimer's drug candidate could not be shown to slow dementia progression in two drug trials, leaving rivals Biogen and Eisai as leaders in a high-stakes race to launch a treatment for the ...

Roche RHHBY announced results from a late-stage study evaluating its investigational candidate, giredestrant, in combination with palbociclib for patients with estrogen receptor (ER)-positive, human ...

(Reuters) - Roche's Alzheimer's drug candidate could not be shown to slow dementia progression in two drug trials, leaving rivals Biogen and Eisai as leaders in a high-stakes race to launch a ...